Spin dynamics in a dissipative environment: from quantal to classical

We address the problem of spin dynamics in the presence of a thermal bath, by solving exactly the appropriate quantum master equations with continued-fraction methods. The crossover region between the quantum and classical domains is studied by increasing the spin value S, and the asymptote for the classical absorption spectra is eventually recovered. Along with the recognized relevance of the coupling strength, we show the critical role played by the structure of the system-environment interaction in the emergence of classical phenomenology.Comment: 4 pp., 3 figs., resubmitted to Phys. Rev. Lett. with minor change

Quasi two-dimensional antiferromagnet on a triangular lattice RbFe(MoO4)2

RbFe(MoO4)2 is a rare example of a nearly two-dimensional Heisenberg antiferromagnet on a triangular lattice. Magnetic resonance spectra and magnetization curves reveal that the system has a layered spin structure with six magnetic sublattices. The sublattices within a layer are arranged in a triangular manner with the magnetization vectors 120 degree apart. The H-T phase diagram, containing at least five different magnetic phases is constructed. In zero field, RbFe(MoO4)2 undergoes a phase transition at T_N=3.8 K into a non-collinear triangular spin structure with all the spins confined in the basal plane. The application of an in-plane magnetic field induces a collinear spin state between the fields H_c1=47 kOe and H_c2=71 kOe and produces a magnetization plateau at one-third of the saturation moment. Both the ESR and the magnetization measurements also clearly indicate an additional first-order phase transition in a field of 35 kOe. The exact nature of this phase transition is uncertain.Comment: 9 pages incl 11 figure

Fluctuation-induced phase in CsCuCl3 in transverse magnetic field: Theory

CsCuCl3 is a quantum triangular antiferromagnet, ferromagnetically stacked, with an incommensurate (IC) structure due to a Dzyaloshinskii-Moriya interaction. Because of the classical degeneracy caused by the frustration, fluctuations in CsCuCl3 have extraordinarily large effects, such as the phase transition in longitudinal magnetic field (normal to the planes, parallel to the IC wavenumber q) and the plateau in q in transverse field (perpendicular to q). We argue that fluctuations are responsible also for the new IC phase discovered in transverse field near the Neel temperature T_N, by T. Werner et al. [Solid State Commun. 102, p.609 (1997)]. We develop and analyse the corresponding minimal Landau theory; the effects of fluctuations on the frustration are included phenomenologically, by means of a biquadratic term. The Landau theory gives two IC phases, one familiar from previous studies; properties of the new IC phase, which occupies a pocket of the temperature-field phase diagram near T_N, agree qualitatively with those of the new phase found experimentally.Comment: 12 pages, revtex, 4 postscript figures, submitted to J. Phys: Condens. Matte

Fokker-Planck and Landau-Lifshitz-Bloch Equations for Classical Ferromagnets

A macroscopic equation of motion for the magnetization of a ferromagnet at elevated temperatures should contain both transverse and longitudinal relaxation terms and interpolate between Landau-Lifshitz equation at low temperatures and the Bloch equation at high temperatures. It is shown that for the classical model where spin-bath interactions are described by stochastic Langevin fields and spin-spin interactions are treated within the mean-field approximation (MFA), such a ``Landau-Lifshitz-Bloch'' (LLB) equation can be derived exactly from the Fokker-Planck equation, if the external conditions change slowly enough. For weakly anisotropic ferromagnets within the MFA the LLB equation can be written in a macroscopic form based on the free-energy functional interpolating between the Landau free energy near T_C and the ``micromagnetic'' free energy, which neglects changes of the magnetization magnitude |{\bf M}|, at low temperatures.Comment: 9 pages, no figures, a small error correcte

Interventions for treating depression after stroke

Background: Depression is an important consequence of stroke that impacts on recovery yet is often not detected or inadequately treated. This is an update of a Cochrane review first published in 2004. Objectives: To determine whether pharmaceutical, psychological, or electroconvulsive treatment (ECT) of depression in patients with stroke can improve outcome. Search strategy: We searched the trials registers of the Cochrane Stroke Group (last searched October 2007) and the Cochrane Depression Anxiety and Neurosis Group (last searched February 2008). In addition, we searched the Cochrane Central Register of Controlled Trials (The Cochrane Library, Issue 1, 2008), MEDLINE (1966 to May 2006), EMBASE (1980 to May 2006), CINAHL (1982 to May 2006), PsycINFO (1967 to May 2006) and other databases. We also searched reference lists, clinical trials registers, conference proceedings and dissertation abstracts, and contacted authors, researchers and pharmaceutical companies. Selection criteria: Randomised controlled trials comparing pharmaceutical agents with placebo, or various forms of psychotherapy or ECT with standard care (or attention control), in patients with stroke, with the intention of treating depression. Data collection and analysis: Two review authors selected trials for inclusion and assessed methodological quality; three review authors extracted, cross-checked and entered data. Primary analyses were the prevalence of diagnosable depressive disorder at the end of treatment. Secondary outcomes included depression scores on standard scales, physical function, death, recurrent stroke and adverse effects. Main results: Sixteen trials (17 interventions), with 1655 participants, were included in the review. Data were available for 13 pharmaceutical agents, and four trials of psychotherapy. There were no trials of ECT. The analyses were complicated by the lack of standardised diagnostic and outcome criteria, and differing analytic methods. There was some evidence of benefit of pharmacotherapy in terms of a complete remission of depression and a reduction (improvement) in scores on depression rating scales, but there was also evidence of an associated increase in adverse events. There was no evidence of benefit of psychotherapy. Authors' conclusions: A small but significant effect of pharmacotherapy (not psychotherapy) on treating depression and reducing depressive symptoms was found, as was a significant increase in adverse events. More research is required before recommendations can be made about the routine use of such treatments

Dialectics and Implications of Natural Neurotropic Autoantibodies in Neurological Disease and Rehabilitation

The role of natural idiotypic (Id-Abs) and anti-idiotypic (AId-Abs) autoantibodies against neuro-antigens observed in different neurological disorders is not fully understood. In particular, limited experimental evidence has been provided concerning the qualitative and quantitative serological response after acute injuries of the central nervous system or during chronic mental diseases. In this study, we analyzed the specific Id-Abs and AId-Abs serological reactivities against 4 neuro-antigens in a large population of patients with ischemic stroke, schizophrenia, as well as healthy individuals. Patients with ischemic stroke were tested at different time points following the acute stroke episode and a correlation was attempted between autoantibodies response and different patterns of functional recovery. Results showed variable and detectable Id-Abs and AId-Abs in different proportions of all three populations of subjects. Among patients with different functional recovery after ischemic stroke, a difference in time-related trends of Id-Abs and AId-Abs was encountered. Our observations suggest that changes in the production of natural neurotropic Abs may engender a positive homeostatic, beside a possible pathogenic effect, in specific neurological disorders

Neurotrophic factors in patients with primary open-angle glaucoma and age-related cataract. Part 2. Brain-derived neurotrophic factor

Purpose. To study the content of the brain-derived neurotrophic factor (BDNF) in the aqueous humor (AH), lacrimal fluid (LF), and blood serum (BS) in patients with primary open-angle glaucoma (POAG) and age-related cataract.Material and methods. We examined 141 people (141 eyes), of them 55 patients with POAG combined with age-related cataract, 57 patients with age-related cataract, and 29 persons without ophthalmic pathology. The content of BDNF in the AH (except healthy individuals), LF and BS was studied.Results. The levels of BDNF in LF and BS did not differ in cataract patients and healthy controls. Compared to patients with cataract the concentration of BDNF in patients with cataract and POAG was significantly reduced in the AH and LF (P<0.001), and in BS (P<0.05). In the early stage of POAG there was a significant decrease in the level of BDNF in all studied biological fluids (P<0.001), particularly pronounced in the AH – by more than 2.5 times. In subsequent stages, the BDNF levels consequentially increased in comparison with the early POAG, remaining, however, lower relative to the cataract patients (the difference was significant for the AH and LF, the correlation of the content of BDNF in the AH with the perimetric index VFI was negative: correlation coefficient r=-0.404, P=0.002). The level of BDNF in the AH showed a strong correlation with its concentration in the LF (r=0.66, P<0.000). A formula is proposed for an approximate calculation of the level of BDNF in the AH by its content in the LF.Conclusion. The content of BDNF in the AH, LF and BS is significantly reduced in patients with POAG, especially in its early stage. In subsequent stages, reduction of the level of BDNF in the AH and LF is consistently less pronounced, but remains decreased. A strong correlation of the content of BDNF in the AH with its concentration in the LF is established, which opens up new opportunities for indirect assessment of the level of BDNF in the AH of patients with POAG

Surgical outcomes in patients with drug-resistant bilateral temporal lobe epilepsy confirmed via magnetic resonance imaging

Introduction. In patients with drug-resistant temporal lobe epilepsy (TLE), surgical treatment is aimed to resect an epileptogenic zone (EZ) followed by seizure control. Despite complicated EZ location, surgical resection should be considered as a treatment of choice in bilateral TLE. Objective: to evaluate surgical outcomes and factors contributing to outcomes in patients with drug-resistant bilateral TLE confirmed via magnetic resonance imaging. Materials and methods. The study included patients with unilateral (n = 50) and bilateral (n = 50) temporal lobe involvement. The results of surgical treatment were evaluated according to the classification of J. Engel (1993). Results. Favorable outcomes of surgical treatment (Engel I and Engel II) in the group with unilateral temporal lobe involvement were found in 98% of patients after 12 months, in 88% after 24 months, and in 100% after 48 and 60 months after surgery. In the group with bilateral temporal lobe involvement outcomes of surgical treatment were favorable in 41% of patients after 12 months, in 50% after 24 months, in 39% after 48 months, and in 50% of patients after 60 months post-surgery. Conclusion. Early onset, burdened perinatal history, and MRI-confirmed left temporal lobe involvement contribute to the poor outcome (Engel III and Engel IV) in the bilateral TLE group. Engel I outcomes were more common in the patients with unilateral TLE while Engel IIIV outcomes were more common in the patients with bilateral TLE